(S)-Ceralasertib
Based on 2 publication(s) in Google Scholar
(S)-Ceralasertib ((S)-AZD6738) is the S-enantiomer of Ceralasertib (HY-19323). (S)-Ceralasertib is the inhibitor for ataxia telangiectasia mutated and rad3 related (ATR).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.97%
- CAS. Nr.: 1352226-87-9
- Formel: C20H24N6O2S
- Molecular Weight:412.51
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-101566
ElimusertibATR Inhibitor -
HY-145817A
lunresertibPKMYT1 Inhibitor -
HY-19323
CeralasertibATR Inhibitor -
HY-15339
CVT-313CDK2 Inhibitor -
HY-14731
VE-821ATR Inhibitor -
HY-139609
CamonsertibATR Inhibitor -
HY-15557
AZ20ATR Inhibitor -
HY-111787
Elzovantinibc-Met/HGFR Inhibitor -
HY-111451
TuvusertibATR Inhibitor -
HY-145312
ATR-IN-4ATR Inhibitor -
HY-101566R
Elimusertib (Standard)ATR Inhibitor
Publications Citing Use of MedChemExpress (MCE) (S)-Ceralasertib
More
Biologische Aktivität
Beschreibung
In Vitro
(S)-Ceralasertib (10 μM, 24 h) inhibits the Etoposide (HY-13629)-induced yH2AX increase in MDA-MB-231 wildtype cell[3].
(S)-Ceralasertib (250 nM, 72 h) promotes SN-38 (HY-13704)-induced chromosomal breaks in A-673 and TC-71 cells, enhances the cytotoxicity of SN-38 (HY-13704) in A-673 and TC-71[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A-673 and TC-71
-
Concentration:250 nM
-
Incubation Time:72 h
-
Result:Enhanced the cytotoxicity of SN-38, inhibited cell viability in A-673 and TC-71.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 1352226-87-9
-
Appearance Solid
-
Molecular Weight 412.51
-
Formel C20H24N6O2S
-
Color Light yellow to yellow
-
SMILES
O=[S@](C1(CC1)C2=NC(C3=C4C(NC=C4)=NC=C3)=NC(N5CCOC[C@H]5C)=C2)(C)=N
-
Synonyms
(S)-AZD6738
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2024 Nov 12;15(1):9515. PMID: 39532854 -
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (242.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[2]. Foote KM, et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutatedand Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J Med Chem. 2018 Nov 21;61(22):9889-9907. [Content Brief]
[3]. Espinar L, et al., Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity. Nat Commun. 2024 Nov 12;15(1):9515. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4242 mL | 12.1209 mL | 24.2418 mL | 60.6046 mL |
| 5 mM | 0.4848 mL | 2.4242 mL | 4.8484 mL | 12.1209 mL | |
| 10 mM | 0.2424 mL | 1.2121 mL | 2.4242 mL | 6.0605 mL | |
| 15 mM | 0.1616 mL | 0.8081 mL | 1.6161 mL | 4.0403 mL | |
| 20 mM | 0.1212 mL | 0.6060 mL | 1.2121 mL | 3.0302 mL | |
| 25 mM | 0.0970 mL | 0.4848 mL | 0.9697 mL | 2.4242 mL | |
| 30 mM | 0.0808 mL | 0.4040 mL | 0.8081 mL | 2.0202 mL | |
| 40 mM | 0.0606 mL | 0.3030 mL | 0.6060 mL | 1.5151 mL | |
| 50 mM | 0.0485 mL | 0.2424 mL | 0.4848 mL | 1.2121 mL | |
| 60 mM | 0.0404 mL | 0.2020 mL | 0.4040 mL | 1.0101 mL | |
| 80 mM | 0.0303 mL | 0.1515 mL | 0.3030 mL | 0.7576 mL | |
| 100 mM | 0.0242 mL | 0.1212 mL | 0.2424 mL | 0.6060 mL |
(S)-Ceralasertib Related Classifications
HY-19323A Related Classifications
Powered by Bioz